Urotensin II: The Most Potent Endogenous Vasoconstrictor and Its Receptor GPR14 in Cardiovascular and Metabolic Research

# Urotensin II: The Most Potent Endogenous Vasoconstrictor and Its Receptor GPR14 in Cardiovascular and Metabolic Research

The peptide family responsible for the most powerful vasoconstriction in the mammalian cardiovascular system is not angiotensin II or endothelin — it is urotensin II (U-II), a cyclic neuropeptide that was deorphanized as the endogenous ligand for the human orphan receptor GPR14 in the landmark 2000 Nature paper by Ames et al. Despite its name suggesting a urinary function (derived from fish urotensin biology), mammalian U-II has emerged as a cardiovascular hormone with potency exceeding all other known vasoconstrictors, while simultaneously exerting complex effects on cardiac function, metabolic syndrome, and the central nervous system. This guide covers the evolutionary history, molecular pharmacology, receptor biology, vascular and cardiac mechanisms, and research implications of the urotensin II system.

Evolutionary Origins and Discovery

Urotensin II has one of the longest discovery histories of any mammalian neuropeptide — identified decades before its mammalian significance was appreciated.

Fish urotensins. In the 1960s-1970s, Bern, Pearson, and colleagues isolated peptides from the caudal neurosecretory system (CNSS) of teleost fish — a specialized neuroendocrine organ in the tail region with no clear mammalian homolog. From this system, they isolated urotensin I (CRH/sauvagine family, vasoactive) and urotensin II (somatostatin-related structure, vasoactive). Goat fish (Gillichthys mirabilis) urotensin II was characterized as an 11-amino acid peptide with a cyclic structure formed by an intramolecular cysteine disulfide bond — providing potent vasoconstrictor activity in isolated vascular preparations.

Mammalian urotensin II. For nearly two decades, urotensin II was considered a fish-specific peptide with no clear mammalian equivalent. The paradigm shifted when molecular biology revealed GPR14 — a class A GPCR expressed in human heart, aorta, and brain — as an orphan receptor with significant homology to somatostatin and opioid receptors.

The 2000 Nature paper. Ames RS, Sarau HM, Chambers JK, and colleagues at SmithKline Beecham Pharmaceuticals screened tissue extracts against GPR14-expressing cells and identified the endogenous ligand as human urotensin II — a peptide they cloned from human spinal cord cDNA. The paper (Ames RS et al., Nature. 2000;401(6750):282-286. PMID: 10499587 — note: this is the 1999 paper; the 2000 confirmation was Itoh H et al.) provided the first evidence that U-II is not only conserved in mammals but produces extraordinary vasoconstriction in primate coronary arteries — with a potency exceeding endothelin-1 in some assays by 10-100-fold. This finding immediately attracted intense cardiovascular research interest.

Molecular Structure: The Conserved Cyclic Core

Human urotensin II (hU-II) is an 11-amino acid peptide: Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-NH₂, where the brackets denote the intramolecular disulfide bond between Cys7 and Cys12 (in the 11-aa form, positions 5 and 10 in the cyclic segment) that creates a six-residue cyclic ring.

The cyclic hexapeptide core (c[CFWKYc]) is the pharmacophore. Truncation studies and SAR demonstrate:

• •The disulfide bond is essential — reduction destroys activity
• •Trp7 and Lys8 are critical for receptor binding
• •The C-terminal amide is required
• •The linear N-terminal segment (Glu-Thr-Pro-Asp) modulates potency but is not essential

This six-residue cyclic core is conserved across 600 million years of vertebrate evolution — virtually identical in structure from teleost fish to humans. The extraordinary evolutionary conservation implies fundamental physiological importance and suggests the core pharmacophore exerts selective pressure that resists mutational drift.

Urotensin II-related peptide (URP). A second endogenous GPR14 ligand was identified in 2003: urotensin II-related peptide (URP), an 8-amino acid peptide encoded by a separate gene (UTS2B). URP shares the same cyclic hexapeptide core (CFWKYC) as U-II but lacks the N-terminal Glu-Thr-Pro-Asp extension. URP binds GPR14 with affinity comparable to U-II and has similar vasoconstrictor activity. URP expression is distinct from U-II — particularly enriched in CNS neurons rather than cardiovascular tissue — suggesting complementary rather than redundant physiological roles.

In mammals, two genes encode urotensin system peptides:

• •UTS2 (human chr 1p36): encodes prepro-U-II → mature U-II
• •UTS2B (human chr Xq23): encodes prepro-URP → mature URP

Receptor Biology: GPR14 (UT Receptor)

The urotensin II receptor, now designated UT (or UTS2R, or GPR14), is a class A GPCR.

Signaling. UT couples to Gαq/11 as the primary pathway, activating PLC → IP₃ → intracellular Ca²⁺ → smooth muscle contraction. This Gαq coupling mediates the vasoconstrictor action. UT also engages:

• •Gαi/o in some cell types → ERK1/2 activation via Gβγ
• •Gα12/13 → Rho/ROCK activation → cytoskeletal changes, smooth muscle tone
• •β-arrestin recruitment → desensitization and internalization; may also mediate anti-apoptotic ERK signaling

The multiplicity of UT signaling pathways explains how U-II can exert both vasoconstriction (Gαq/Gα12-Ca²⁺ and Rho/ROCK) and longer-term trophic effects (ERK/β-arrestin → cell proliferation, hypertrophy).

UT expression. GPR14/UT is highly expressed in:

• •Vascular smooth muscle cells (VSMCs): the primary mediator of vasoconstriction; coronary > systemic vascular beds
• •Endothelium: where U-II can trigger nitric oxide (NO) and prostacyclin release — vasodilatory counterregulation
• •Heart: cardiomyocytes, cardiac fibroblasts — directly driving hypertrophy and fibrosis
• •Kidney: glomerular mesangial cells, tubular epithelium — renal hemodynamics and filtration regulation
• •Brain: brainstem cardiovascular centers, hypothalamus, cortex
• •Adrenal gland: U-II stimulates catecholamine and aldosterone release
• •Skeletal muscle and liver: relevant to metabolic syndrome actions
• •Pancreas: β-cells express UT; U-II modulates insulin secretion

Vasoconstriction: Potency, Regional Heterogeneity, and the Endothelin Comparison

The statement that U-II is the most potent vasoconstrictor known requires qualification — it is context-dependent.

Potency vs. endothelin-1 (ET-1). In isolated primate coronary artery preparations, human U-II produces concentration-response curves with EC50 in the picomolar range (~1-10 pM), compared to ET-1 which achieves comparable maximal contraction in the nanomolar range. This ~10-100-fold potency advantage in primate coronary vessels is the basis for calling U-II "the most potent vasoconstrictor known." However, in rodent vessels, U-II is substantially less potent — EC50 in the nanomolar range — which reflects a pharmacological difference in rodent UT receptor pharmacology. This species difference has complicated preclinical model development.

Regional heterogeneity. U-II-induced vasoconstriction is not uniform:

• •Maximum potency: primate coronary arteries, internal mammary artery, saphenous vein
• •Intermediate: aorta, mesenteric vessels
• •Vasodilation: rat thoracic aorta (NO-dependent vasodilation via endothelial UT), pulmonary vasculature in some conditions
• •No effect: cerebral vessels (UT expression is low on cerebral vascular smooth muscle)

The vasoconstrictor vs. vasodilatory outcome depends on:

1. UT expression ratio: smooth muscle vs. endothelial UT expression. Endothelial UT → NO → vasodilation; smooth muscle UT → Ca²⁺ → contraction

2. Vascular tone at baseline: at high basal tone, U-II may preferentially vasodilate; at low basal tone, vasoconstriction dominates

3. Species differences: rat vessels respond differently from primate vessels

This complexity means U-II is not simply "the most potent vasoconstrictor" but a vessel-type-specific and species-specific regulator with bidirectional potential.

Cardiac Effects: Hypertrophy, Fibrosis, and Heart Failure

Beyond acute vasoconstriction, U-II drives chronic cardiac remodeling — a pathophysiological consequence of chronic UT activation.

Cardiomyocyte hypertrophy. U-II stimulates cardiomyocyte protein synthesis and cell enlargement via MAPK (ERK1/2, p38) and calcineurin/NFAT pathways — the same hypertrophic signaling cascades activated by angiotensin II and endothelin-1. This hypertrophic response is independent of hemodynamic load, suggesting direct myocardial effects.

Cardiac fibrosis. U-II activates cardiac fibroblasts via UT/Gαq → TGF-β upregulation → collagen I/III deposition. Increased extracellular matrix stiffness — the hallmark of myocardial fibrosis — reduces cardiac compliance and contributes to diastolic dysfunction.

Inotropic effects. U-II has complex inotropic effects: positive inotropy at low concentrations (increased contractility via Ca²⁺ influx) and negative inotropy at high concentrations (secondary to coronary vasoconstriction reducing perfusion). In heart failure patients, where U-II plasma levels are elevated, the net cardiac effect may shift toward impaired function.

Heart failure and plasma U-II levels. A critical translational observation is that plasma U-II is elevated in heart failure patients, with levels correlating with disease severity. Elevated U-II could be both a marker and a mediator of adverse cardiac remodeling — with chronic UT activation driving hypertrophy and fibrosis that worsens ventricular function. Similar plasma U-II elevations have been documented in:

• •Chronic heart failure (CHF)
• •Pulmonary arterial hypertension (PAH)
• •Essential hypertension
• •Coronary artery disease (CAD)
• •Renal failure (impaired U-II clearance)
• •Type 2 diabetes and metabolic syndrome

Metabolic Syndrome: Insulin Resistance, Dyslipidemia, and Obesity

The discovery of UT expression in metabolically active tissues (skeletal muscle, liver, pancreas, adipose) revealed that U-II participates in metabolic regulation — with pathological consequences.

Insulin resistance. U-II impairs insulin signaling in skeletal muscle and liver by activating PKC isoforms that serine-phosphorylate IRS-1, blocking the PI3K→Akt→GLUT4 translocation pathway. Chronic U-II exposure reduces glucose uptake in muscle, contributing to insulin resistance. Plasma U-II is elevated in patients with type 2 diabetes and correlates with HOMA-IR (a measure of insulin resistance).

Pancreatic β-cell modulation. UT on pancreatic β-cells responds to U-II with inhibition of glucose-stimulated insulin secretion — a pro-diabetic effect. The mechanism involves Gαi coupling in β-cells → reduced cAMP → impaired insulin exocytosis.

Dyslipidemia. U-II in the liver stimulates lipogenesis (increased triglyceride synthesis) via sterol regulatory element-binding protein 1c (SREBP-1c). Serum triglycerides and LDL-cholesterol correlate with plasma U-II in observational studies, though causality direction is uncertain.

Obesity. The U-II system interacts with adipokines: adiponectin (anti-inflammatory adipokine) is negatively correlated with plasma U-II. In visceral obesity, elevated U-II may contribute to both insulin resistance and vascular dysfunction, completing a pathophysiological nexus of cardiovascular and metabolic risk.

Renal Function and Hypertension

Renal hemodynamics. UT is expressed on glomerular mesangial cells, afferent arterioles, and tubular epithelium. U-II constricts mesangial cells (reducing glomerular filtration area), reduces glomerular blood flow, and increases intraglomerular pressure — effects that parallel angiotensin II in promoting hyperfiltration injury with chronic exposure.

Sodium and water handling. U-II modulates renal tubular sodium reabsorption. In proximal tubule cells, U-II via Gαq increases Na⁺/K⁺-ATPase activity, promoting sodium retention — a mechanism contributing to hypertension. This tubular U-II action parallels aldosterone and angiotensin II.

Elevated U-II in renal disease. U-II plasma levels rise dramatically in chronic kidney disease (CKD) — partly because the kidney is a major site of U-II clearance, and partly because the diseased kidney upregulates U-II production. The elevated U-II in CKD contributes to accelerated cardiovascular risk in renal failure patients.

Central Nervous System: Autonomic and Behavioral Effects

Despite being classified primarily as a cardiovascular peptide, U-II and URP are present in the CNS with functional consequences.

Brainstem cardiovascular control. UT is expressed in brainstem cardiovascular regulatory nuclei (NTS, RVLM). Central U-II administration alters blood pressure and heart rate through autonomic mechanisms. URP, with its CNS-enriched expression, may be the primary urotensin system signal in brainstem autonomic circuits.

Corticotropin and HPA. U-II in the hypothalamus and adrenal gland can activate the HPA axis — increasing ACTH and cortisol in some experimental paradigms. This positions urotensin II as a potential cardiovascular-HPA axis co-regulator.

Motor and behavioral effects. Intracerebroventricular U-II produces hyperkinesia, tremor, and anxiety-like behavior in rodents — effects consistent with sympathetic activation. The behavioral significance of central URP (the CNS-enriched form) remains incompletely characterized.

Research Tools and UT Receptor Antagonists

Palosuran is the most clinically advanced UT antagonist. Actelion conducted Phase II trials in diabetic nephropathy and chronic kidney disease, with mixed results — primary endpoints on renal function were not consistently met, though biomarker data confirmed target engagement and some secondary endpoints showed improvement. Phase III was not pursued. This reflects the challenge of translating UT biology from in vitro/rodent studies to human therapeutics, partly because of the species potency gap.

Urotensin II vs. Endothelin-1: A Structural and Pharmacological Comparison

The comparison highlights why endothelin antagonists succeeded clinically (PAH is an approved indication with clear benefit) while urotensin antagonists have not: the species potency gap complicates preclinical models, the tissue distribution creates opposing vascular effects, and the disease context with clearest U-II involvement (heart failure, metabolic syndrome) has less defined UT-specific pathology than PAH has defined ET-1 pathology.

Current Frontiers

Heart failure biomarker. Plasma U-II as a prognostic biomarker in heart failure has been examined in cohort studies. Its correlation with ejection fraction, BNP, and mortality risk makes it a candidate prognostic marker — though it has not been validated for clinical use.

Pulmonary arterial hypertension. Elevated U-II in PAH patients, combined with UT expression on pulmonary VSMCs, makes PAH a target for UT antagonism — the same rationale that drove successful ET-1 antagonist development. SB-706375 reduced pulmonary pressure in animal PAH models. A clinical trial of UT antagonism in PAH has not yet been completed.

Metabolic syndrome as primary indication. Given U-II's role in insulin resistance, β-cell inhibition, and dyslipidemia, type 2 diabetes and metabolic syndrome represent a therapeutic target distinct from cardiovascular PAH approaches. The combination of vascular and metabolic effects makes U-II a plausible contributor to the cardiometabolic risk cluster.

Biased UT agonism. Like MOR and other GPCRs, UT may be amenable to biased agonism — compounds that selectively activate G protein pathways (e.g., acute vasoregulation) while minimizing β-arrestin recruitment (desensitization, internalization). Biased UT ligands could potentially separate therapeutic vasoregulatory actions from adverse cardiac trophic effects.

URP-specific biology. Because URP is CNS-enriched and arises from a separate gene (UTS2B), it may have distinct physiological functions from U-II. The specific circuit functions of brainstem URP neurons, their projection targets, and their role in autonomic cardiovascular regulation are underexplored research frontiers.

Conclusion

Urotensin II occupies a unique position in cardiovascular pharmacology: an ancient, structurally conserved cyclic peptide that deorphanized GPR14 in 2000 and revealed the most potent vasoconstriction yet observed from an endogenous mammalian peptide. Its biology spans vasoconstriction, cardiac hypertrophy, renal hemodynamics, metabolic syndrome, and CNS autonomic regulation — reflecting widespread UT receptor distribution across tissues that are central to cardiometabolic homeostasis. Elevated plasma U-II in heart failure, diabetes, hypertension, and CKD positions it as a disease-associated peptide with both biomarker and therapeutic potential, though clinical translation of UT antagonists has proven challenging. The species pharmacology gap, bidirectional vascular effects, and complex tissue-specific signaling make urotensin II one of the most biologically rich but pharmacologically nuanced targets in the neuropeptide field.

Key Research References

• •Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282-286. PMID: 10499587
• •Itoh H, Okabe K, Kanada K, et al. Urotensin II is an endogenous ligand for a G-protein-coupled receptor. FEBS Lett. 2000;478(1-2):1-5. PMID: 10922464
• •Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA. 1998;95(26):15803-15808. PMID: 9861054
• •Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131(7):1262-1274. PMID: 11090100
• •Nothacker HP, Wang Z, McNeill AM, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol. 1999;1(6):383-385. PMID: 10559967
• •Vaudry H, Do Rego JC, Le Mevel JC, et al. Urotensin II, from fish to human. Ann N Y Acad Sci. 2010;1200:53-66. PMID: 20633133

---

This article is intended for Research Use Only (RUO). Urotensin II, URP, GPR14 ligands, and related analogs are not approved for human therapeutic use. Information presented is for scientific education and research purposes only. Peptides.SO does not provide medical advice, and no content herein should be construed as guidance for human administration.